initi buy trim- tough
initi buy believ co new improv trim
platform reli endosom lyse escap may best-in-
class w/ efficaci safeti advantag recent enter clinic
w/ two lead program aatd rare diseas hbv could larg
market oppti w/ near-term partner potenti though competit notabl
believ could succeed base current posit
jefferi left lead bookrunn januari secondari offer
aatd rel larg rare indic rnai approach
may direct meaning benefit deplet toxic accumul
rnai may actual restor normal function hepatocyt pt aatd base
feedback receiv elig aatd popul underdiagnos
believ avail aro-aat better understand diseas led
interest competitor grow market
hbv major indic -- one mani patient high unmet need
 believ pursu via differenti approach
uniqu target two pathway import viru success includ cccdna
integr viru aro-hbv act upstream nucleosid analog inhibit viral
replic product viral protein treatment goal reduc sag
maintain state control lt chronic hbv believ could partner
hbv maxim ww potenti
collabor lead add upsid oppti
collabor valid approach management give access
expertis cardiovascular diseas w/ strong commerci intern presenc
platform potenti pursu tgt outsid liver trim platform leverag
know-how rnai risc w/ quick develop turnaround design new
molecul w/ two trigger activ rnai silenc current use administr
intend pursu rout includ inhal could fuel lt growth
data aatd hbv data two recent start
ph well ph ii strateg updat data de-risk safeti major hurdl
rnai also expect file two program w/ buy
pt blend dcf prob-adj ep analys w/ aatd account hbv
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
show promis initi safeti data healthi
volunt new platform-bas aro-hbv
aro-aat end
aro-hbv well toler first patient
dose seriou advers event
initi clinic program
track
competitor develop line current
aro-hbv aro-aat healthi volunt studi read
faster expect
favor level sag clearanc
better expect earli data program
faster expect develop preclin
addit partnership larg biotech/pharma
price use blend dcf ep
delay unexpect safeti concern aro-hbv
delay recruit hbv patient lead
later anticip studi read-out
unfavor initi safeti data patient
lack efficaci sag clearanc hbv reduct
mutant protein
lack advanc preclin program
price use blend dcf ep multipl
strong mechanist rational new gener
rnai platform build previou clinic experi
success w/ aro-hbv would tap larg hbv
market signific unmet need
strong scientif rational target cccdna
well integr viral dna order achiev
function hbv cure measur sag
aro-aat underappreci valu driver
storag diseas aspect aatd
follow platform valid success follow-on
indic valid partnership w/
would addit upsid
start dose healthi volunt hbv ph
cta file ph initi
cta file ph initi
cta file ph initi
potenti initi data hbv ph
potenti initi data ph
cta file ph initi
page
pleas see import disclosur inform page report
page
pleas see import disclosur inform page report
execut summari compani essenti relaunch new improv rnai platform could best-in-class platform technolog key
believ control sever lever includ stabil chemistri pk enhanc linker chemistri trigger use
activ silenc proprietari management team may enough accumul collect know-how/understand give edg
space initi indic pursu includ aatd primari focu patient involv liver diseas hbv larg market indic
break aatd would allow leverag rare diseas develop current favor regulatori pathway anticip partner
hbv program given ww preval diseas excit approach hbv believ market opportun major
aatd hbv program recent enter clinic gradual de-risk safeti efficaci increas confid valu
aatd program leverag rare diseas approach could allow pursu acceler develop path
strong price aatd program wholli own believ could drive out-year valuat addit aatd
market somewhat undefin cross goal line aatd could lead greater diagnosi upsid estim
program also pursu aatd adverum azn etc primarili focus liver believ competitor effort
actual benefit compani help find aatd patient grow market though target pt liver-bas aatd
may seem limit market oppti may allow aro-aat provid benefit balanc efficaci safeti
hbv larg market indic arwr differenti approach could allow crack code challeng
multifacet viru estim hbv infect patient exist make indic major market opportun
competit barrier current stand said competitor pursuit hbv debat around market develop
antivir gene-edit approach believ arwr approach use two trigger activ w/ endosom lysi could improv chanc
success find optim patient maneuv regulatori path could challeng spoke expert believ arwr
strategi sound hbv arwr aro-hbv potenti deplet cccdna activ well integr viru believ could
succeed efficaci endpoint maxim control viru long period
success partner program includ valuat cardiovascular target pursu could lead
meaning upsid addit provid valid arwr approach partnership allow potenti large-cap
biotech compani leverag intern presenc expertis arwr rnai technolog
trim technolog platform key valu driver investor appreci arwr trim technolog new improv
reli endosom lyse believ could lead wider therapeut window co expert spoke believ technolog
could best-in-class particularli initi indic pursu co initi use administr deliv rnai believ
technolog suit rout administr well includ inhal believ success pursu specif organ rnai
could lead substanti long-term valu
page
pleas see import disclosur inform page report
establish price target
base blend two methodolog
use discount cash flow dcf analysi
arwr futur cash flow incorpor
discount rate termin growth rate
believ appropri compani
arwr size stage develop yield
theoret fair valu probabl
adjust assum overal likelihood
program success would yield share valuat
also use multipl out-year probability-
weight ep appli multipl
believ appropri given compar
compani ep estim
discount back per year appli
blend likelihood success would yield
share valuat
page
pleas see import disclosur inform page report
pv pv termin enterpris net equiti dilut share potenti unadjust share termin growth wacc/discount jefferi estim compani reportstermin growth rate discount rate
establish price target
base blend two methodolog
valuat multipl probability-
use discount cash flow dcf analysi
arwr futur cash flow incorpor
discount rate termin growth rate
believ appropri compani
arwr size stage develop yield
theoret fair valu probabl
adjust assum overal likelihood
program success would yield share valuat
also use multipl out-year probability-
weight ep appli multipl
believ appropri given compar
compani ep estim
discount back per year appli
blend likelihood success would yield
share valuat
page
pleas see import disclosur inform page report
product futur valuationind probabl successunweight ep contribut ep contribut multipl discount rate
clinic arwr candid aro-aat aro-hbv evalu clinic risk base
dose safeti includ long-term potenti unanticip toler issu addit candid may
demonstr efficaci later stage studi evalu patient
regulatori even arwr product show posit activ clinic trial compani must work
regulatori process gain approv run trial eventu sell/market product ex-
 market process may take longer anticip unforeseen request may delay time market
commerci experi launch product present commerci risk inher
manufactur scale product addit would need effect build salesforc secur
partnership market therapi
financi though current well fund believ requir sever addit capit rais bring
clinic product market would potenti dilut anticip could abl partner
least one addit preclin product return capit howev abl secur partnership
may reliant addit potenti dilut capit rais abl bring product market
page
pleas see import disclosur inform page report
arwr expect mileston pipelin
page
pleas see import disclosur inform page report
producteventtimelinearo-aatpotenti initi data ph studi healthi dose healthi volunt ph dose escal studi initi data ph studi healthi file phase file phase file phase file phase antitrypsin defici phase aro-hbvhepat phase preclin preclin preclin cell carcinoma preclin aro-lpacardiovascular diseas preclin diseas preclin aro-hbv
rnai platform differenti defin compani
page
pleas see import disclosur inform page report
arwr novel trim rnai-bas approach differenti provid strong
rational pursu liver-bas indic
platform technolog evolv
compani tend hedg back-up plan
ultim help de-risk
technolog reli
endosomal/lysosom lyse activ
differenti vs prior dpc platform
trim molecul galnac conjug enter
aspgr receptor function
activ trim reli trigger
compani believ proprietary/differenti
trim primarili protect trade secret
though linker technolog potenti next-gen
ligand work proprietari
tissu specif construct beyond galnac protect
modifi rnai construct quickli find
effect trigger faster competitor addit
consid select sequenc differenti
factor due insight rna-risc interact
page
pleas see import disclosur inform page report
given understand hbv infect chronic rnai approach target
liver may provid optim method treat
page
pleas see import disclosur inform page report
one arwr lead indic hbv
estimate carrier ww die annual liver diseas
acut w/ w/out jaundic chronic lead cirrhosi liver cancer
current soc mainli support includ peg-ifn nucleo ide analog
tenofovir entecavir
aro-hbv -- rnai-bas trim platform therapi -- optim target
integr episom viral dna could potenti lead
reduct sag eag patient
page
data earlier gen program show durabl log
sag reduct eag posit pt
platform discontinu due observ tox signal nhp
high dose despit clinic data show sign success human safeti signal
new gen program aro-hbv shown deep knockdown sag eag well
hbv dna mice
new gen aro-hbv program enter first studi human
previou experi site countri
first subject dose soon expect march
pleas see import disclosur inform page report
estim hbv continu issu develop world
rna-bas therapi superior strategi diseas control
preval estim million chronic
hbv pt posit hbsag world-wide die
 million pt w/ chronic
diseas new case acut disease/year
american die hbv
mechan viral eag sag get transcrib cccdna
recent evid suggest integr viral dna also play
import role suppli sag even cccdna
control rare clear hbv infect signific portion pt
unsuit avail tx face high risk cirrhosi
cancer goal antivir therapi suppress hbv dna
loss eag eag pt loss sag
immun modul pegifna cirrhosi genotyp
short term tx con side effect vs nucleo ide
risk resist better toler con daili treatment
least year indefinit
entecavir tenofovir prefer lamivudin adefovir
telbivudin higher likelihood resist
hbv sale estim
preval chronic hbv
page
pleas see import disclosur inform page report
current hbv treatment goal function cure reduc hbsag
hbv dna integr host
genom exist independ
episom cccdna host cell
hallmark infect presenc hbsag
pt either antigen
hbeag predominantli made
chronic hbv pt hbeag -- viral dna
heavili integr increas risk cirrhosi
liver cancer
complianc exist therapi poor
push cure strategi
hbeag patient modest respons first
treatment goal reduc hbsag
patient immun system recov
control viru
page
pleas see import disclosur inform page report
rnai offer possibl function cure
upstream
viral
viral
arwr rnai base platform potenti best therapeut approach
rule algorithm optim trigger sequenc avoid mirna
interact import
liver specif releas receptor base entri -- endosom lyse necessari
escap
trigger better one increas reach rnai
transcript integr viral dna
earlier rnai strategi focus target sequenc present
howev sequenc lost upon viral dna integr host
genom render strategi ineffici kd genom transcript
trigger cover sequenc gene bank target viral transcript
presenc trigger also reduc risk resist
effect target genom transcript achiev goal
reduc hbsag hbeag patient
reduct hbsag accept trial endpoint
difficult achiev hbeag popul
treat chronic diseas long-term
page
pleas see import disclosur inform page report
singl rnai exampl kd
mrna cccdna miss
aro-hbv data mice demonstr signific reduct hbsag
compar favor compet preclin data
aro-hbv demonstr promis data mice replic log reduct
sag seen mous model ph ii studi would favor
comparison alni aln-hbv qw inject although durabl reduc sag
day reduc lloq
dose mice aro-hbv show log
reduct sag log reduct eag
hbsag
reduct log mous model
page
pleas see import disclosur inform page report
prior dpc platform demonstr encourag hbsag reduct
discontinu due nhp toxic next-gen develop
demonstr strongest sag
reduct seen patient comparison
antivir agent
knockdown log reduct
hbsag
effect persist week
knockdown hbsag
hbeag patient
howev glp toxic studi result nhp death high dose dose
use human use henc earlier gen program discontinu
gen reli endosom disrupt escap may ultim caus toxic nhp
also initi trigger target highli conserv viral dna region lost upon viral integr
host genom limit util therapi hbeag patient viral transcript primarili
deriv non-integr dna
page
pleas see import disclosur inform page report
ph i/ii studi aro-hbv clinic trial design expect
start dose end march
post
first subject
dose
subject
cohorts/ pt
trial conduct new zealand
feb part portion
recruit almost complet
aro-hbv mad cohort pt get dose dose level
number particip
part pk aro-hbv cmax tmax auc
part reduct hbsag day
page
pleas see import disclosur inform page report
frequenc
fda ema
approv therapi hint market potenti therapi clinic
primarili early-stag aro-hbv differenti
approv therapi includ interferon older newer gener
overview current therapi
approv therapi hbv
sever differ treatment modal develop target uniqu compon hbv
immun system activ believ direct overlap arwr approach
page
pleas see import disclosur inform page report
comprehens list chronic hbv asset late stage develop class
viral capsid cccdna format
hbv-deriv lipopeptid inactiv
prodrug hbv polymeras
nucleic acid hybrid rig-i
eventu erad hbv could involv optim combination/multi-facet
approach separ class
page
pleas see import disclosur inform page report
